Ramucirumab : boon or bane
Author
Source
Journal of the Egyptian National Cancer Institute
Issue
Vol. 28, Issue 3 (30 Sep. 2016), pp.133-140, 8 p.
Publisher
Cairo University National Cancer Institute
Publication Date
2016-09-30
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Ramucirumab is the recent addition to the list of monoclonal antibodies being tried in various malignancies.
It has been approved in non-small cell lung cancer, gastric cancer and colorectal cancer after progression of one or more line of therapies in the advanced setting.
Though randomized trials have shown benefit, the cost effectiveness is questionable.
Moreover, the benefits shown are marginal, putting a question mark over its clinical usage.
This review summarizes the latest evidence on ramucirumab.
American Psychological Association (APA)
Tiwari, Priya. 2016. Ramucirumab : boon or bane. Journal of the Egyptian National Cancer Institute،Vol. 28, no. 3, pp.133-140.
https://search.emarefa.net/detail/BIM-708736
Modern Language Association (MLA)
Tiwari, Priya. Ramucirumab : boon or bane. Journal of the Egyptian National Cancer Institute Vol. 28, no. 3 (Sep. 2016), pp.133-140.
https://search.emarefa.net/detail/BIM-708736
American Medical Association (AMA)
Tiwari, Priya. Ramucirumab : boon or bane. Journal of the Egyptian National Cancer Institute. 2016. Vol. 28, no. 3, pp.133-140.
https://search.emarefa.net/detail/BIM-708736
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 138-140
Record ID
BIM-708736
